250 related articles for article (PubMed ID: 8908318)
1. Serum calcitonin in small cell carcinoma of the prostate.
Sim SJ; Glassman AB; Ro JY; Lee JJ; Logothetis CJ; Liu FJ
Ann Clin Lab Sci; 1996; 26(6):487-95. PubMed ID: 8908318
[TBL] [Abstract][Full Text] [Related]
2. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
[TBL] [Abstract][Full Text] [Related]
3. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases.
Wang W; Epstein JI
Am J Surg Pathol; 2008 Jan; 32(1):65-71. PubMed ID: 18162772
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in prostatic carcinomas. A retrospective autopsy study.
Turbat-Herrera EA; Herrera GA; Gore I; Lott RL; Grizzle WE; Bonnin JM
Arch Pathol Lab Med; 1988 Nov; 112(11):1100-5. PubMed ID: 2460064
[TBL] [Abstract][Full Text] [Related]
5. [Small cell carcinoma of the prostate: a report of three patients and a prognostic analysis of cases reported in Japan].
Kageyama S; Narita M; Kim CJ; Hanada E; Sakano Y; Iwaki H; Yoshiki T; Okada Y
Hinyokika Kiyo; 2006 Oct; 52(10):809-15. PubMed ID: 17131874
[TBL] [Abstract][Full Text] [Related]
6. Prostatic adenocarcinoma metastases mimicking small cell carcinoma on fine-needle aspiration.
Parwani AV; Ali SZ
Diagn Cytopathol; 2002 Aug; 27(2):75-9. PubMed ID: 12203872
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological characterization of prostatic small cell carcinoma: a case report and review of the literature].
Wei ZF; Xu H; Wang H; Wei W; Cheng W; Zhou WQ; Ge JP; Zhang ZY; Gao JP; Yin HL
Zhonghua Nan Ke Xue; 2009 Sep; 15(9):829-32. PubMed ID: 19947569
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum progastrin-releasing peptide (31-98) level is a predictor of short response duration after hormonal therapy in metastatic prostate cancer.
Yashi M; Nukui A; Kurokawa S; Ochi M; Ishikawa S; Goto K; Kobayashi Y; Muraishi O; Tokue A
Prostate; 2003 Sep; 56(4):305-12. PubMed ID: 12858359
[TBL] [Abstract][Full Text] [Related]
10. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
11. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
[TBL] [Abstract][Full Text] [Related]
12. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
13. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies.
Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ
J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801
[TBL] [Abstract][Full Text] [Related]
14. Small cell carcinoma of the prostate: a case report and review of the literature.
Aygun C
Md Med J; 1997 Aug; 46(7):353-6. PubMed ID: 9260470
[TBL] [Abstract][Full Text] [Related]
15. Small cell carcinoma of the prostate: an underrecognized entity.
Nadig SN; Deibler AR; El Salamony TM; Hull GW; Bissada NK
Can J Urol; 2001 Feb; 8(1):1207-10. PubMed ID: 11268310
[TBL] [Abstract][Full Text] [Related]
16. [The role of prostate specific antigen in diagnosis of localized adenocarcinoma of the prostate. Nara Uro-Oncology Research Group].
Hirao Y; Ozono S; Kagebayashi Y; Yoshi M; Tani Y; Uemura H; Momose H; Okajima E
Hinyokika Kiyo; 1996 Oct; 42(10):795-804. PubMed ID: 8951478
[TBL] [Abstract][Full Text] [Related]
17. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
18. [Prostatic carcinoma that arose with hearing loss: a case report].
Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
Hinyokika Kiyo; 2007 Jun; 53(6):413-6. PubMed ID: 17628942
[TBL] [Abstract][Full Text] [Related]
19. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
20. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors.
Cussenot O; Villette JM; Cochand-Priollet B; Berthon P
Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]